Abstract:Background and aims: Vascular smooth muscle cell (VSMC) dedifferentiation contributes to neointima formation, which results in various vascular disorders. Intermedin (IMD), a cardiovascular paracrine/autocrine polypeptide, is involved in maintaining circulatory homeostasis. However, whether IMD protects against neointima formation remains largely unknown. The purpose of this study is to investigate the role of IMD in neointima formation and the possible mechanism. Methods: IMD1-53 (100ng/kg/h) or saline water was used on rat carotid-artery balloon-injury model. The mouse left common carotid-artery ligation-injury model was established using IMD-transgenic and C57BL/6J mice. Immunohistochemistry and immunofluorescence staining was used to detect the protein expression in rat carotid arteries. Radioimmunoassay was used to determine the serum IMD level. The hematoxylin andeosin staining was used for carotid arteries morphological testing. In vitro, for rat primary cultured VSMC phenotype transition, proliferation and migration assays, platelet-derived growth factor-BB (PDGF-BB) reagent and IMD1-53 peptide were added to the culture media at the final concentration of 20 ng/mL and 10-7mol/L respectively. Quantification of VSMC proliferation involved MTT and BrdU assay and migration was detected by wound-healing assay. Western blot and realtime PCR were used to detect the protein and mRNA levels of tissues or cells. Results: With the rat carotid-artery balloon-injury model, IMD was significantly downregulated in injured arteries and plasma. Exogenous IMD1-53 greatly inhibited neointima formation and prevented VSMC from switching to a synthetic phenotype. With the left common carotid-artery ligation-injury model, IMD-transgenic mice showed less neointima formation than C57BL/6J mice. PDGF-BB reduced IMD mRNA expression in rat primary cultured VSMCs but increased that of its receptors, calcitonin receptor-like receptor or receptor activity-modifying proteins. Furthermore, PDGF-BB promoted VSMC proliferation and migration and transformed VSMCs to the synthetic phenotype, which was reversed with IMD1-53 treatment. Mechanistically, IMD1-53 maintained the contractile VSMC phenotype via the cyclic adenosine monophosphate/protein kinase A (cAMP/PKA) pathway. Conclusions: IMD attenuated neointima formation both in the rat model of carotid-artery balloon injury and mouse model of common carotid-artery ligation injury. IMD protection may be mediated by maintaining a VSMC contractile phenotype via the cAMP/PKA pathway.

Intermedin1-53 Attenuates Atherosclerotic Plaque Vulnerability by Inhibiting CHOP-mediated Apoptosis and Inflammasome in Macrophages.

Intermedin Inhibits Macrophage Foam-Cell Formation Via Tristetraprolin-Mediated Decay Of Cd36 Mrna

Increased Stability of Phosphatase and Tensin Homolog by Intermedin Leading to Scavenger Receptor A Inhibition of Macrophages Reduces Atherosclerosis in Apolipoprotein E-deficient Mice

Intermedin Ameliorates Atherosclerosis by Increasing Cholesterol Efflux Through the Camp-Pka Pathway in Macrophage RAW264.7 Cell Line

INTERMEDIN1-53 AMELIORATES HOMOCYSTEINE-PROMOTED ATHEROSCLEROTIC CALCIFICATION BY INHIBITING ENDOPLASMIC RETICULUM STRESS

Intermedin Ameliorates Atherosclerosis in Apoe Null Mice by Modifying Lipid Profiles

Intermedin Inhibits Uptake of Oxidized LDL Via CD36 Pathway in RAW264.7 Cells.

Intermedin attenuates macrophage phagocytosis via regulation of the long noncoding RNA Dnm3os/miR-27b-3p/SLAMF7 axis in a mouse model of atherosclerosis in diabetes

Intermedin(1-53) Protects Against Myocardial Fibrosis by Inhibiting Endoplasmic Reticulum Stress and Inflammation Induced by Homocysteine in Apolipoprotein E-Deficient Mice

Intermedin1-53 protects against cardiac hypertrophy by inhibiting endoplasmic reticulum stress via activating AMP-activated protein kinase

Inhibition of Endoplasmic Reticulum Stress by Intermedin1–53 Protects Against Myocardial Injury Through a PI3 Kinase–akt Signaling Pathway

Intermedin1-53 Attenuates Abdominal Aortic Aneurysm by Inhibiting Oxidative Stress

Intermedin1-53 Inhibits NLRP3 Inflammasome Activation by Targeting IRE1α in Cardiac Fibrosis

Endogenous Intermedin Protects Against Intimal Hyperplasia by Inhibiting Endoplasmic Reticulum Stress.

Intermedin reduces neointima formation by regulating vascular smooth muscle cell phenotype via cAMP/PKA pathway

Intermedin Restores Hyperhomocysteinemia-induced Macrophage Polarization and Improves Insulin Resistance in Mice

Intermedin Inhibits the Ox-LDL–Induced Inflammation in RAW264.7 Cells by Affecting Fatty Acid–Binding Protein 4 Through the PKA Pathway

Intermedin Alleviates Diabetic Cardiomyopathy by Up-Regulating CPT-1β through Activation of the Phosphatidyl Inositol 3 Kinase/Protein Kinase B Signaling Pathway

Intermedin1–53 Enhances Angiogenesis and Attenuates Adverse Remodeling Following Myocardial Infarction by Activating AMP-activated Protein Kinase

Intermedin1-53 attenuates vascular smooth muscle cell calcification by inhibiting endoplasmic reticulum stress via cyclic adenosine monophosphate/protein kinase A pathway

Inhibition of Notch1-mediated Inflammation by Intermedin Protects Against Abdominal Aortic Aneurysm Via PI3K/Akt Signaling Pathway